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Regarding "Statement regarding carotid angioplasty 
and stenting" 
To the Editors: 
The recently published "Point of View" (1997;24: 
900) from the Joint Council of The Society for Vascular 
Surgery (SVS) and the International Society for Cardiovas- 
cular Surgery, North American Chapter (ISCVS-NA), was 
stated succinctly and is consistent with the objectives of the 
executive committee of the Carotid Revascularization 
Endarterectomy versus Stent Trial (CREST). The mem- 
bership of the Joint Council meritoriously emphasized that 
the safety and efficacy of carotid angioplasty and stenting 
must be demonstrated before proceeding with a random- 
ized clinical trial. I f  the trial is premature and "clinical 
equipoise ''1 does not exist, many clinicians will consider 
participation unethical. Conversely, ifa trial is delayed until 
such time as the safety and efficacy are unequivocally 
proven, the proponents of the new interventional methods 
will recommend its use without testing its efficacy against 
the gold standard, carotid endarterectomy. This issue of 
"clinical equipoise" and vascular surgeons' participation i
prospective randomized clinical trials has been reviewed 
previously. 2,3 The ethical uncertainty about participating in 
a randomized clinical trial has been addressed by Freed- 
man I in his discussion about "clinical equipoise." He has 
chosen to define the term as a lack of consensus between 
expert clinical groups on the merits of one treatment versus 
another. It may therefore become clinically ethical to con- 
sider participation i a protocol, even though an individual 
clinician's body of knowledge suggests a preference for one 
of the two treatments. Clinicians must recognize that qual- 
ified and competent colleagues in other specialties would 
favor an alternate approach. In addition, they must be 
convinced that the design of the trial will in fact answer a 
question and address the state of equipoise, so that the 
results of the clinical trial will benefit their patients. Al- 
though "clinical equipoise" may be weaker than "theoretic 
equipoise," which extracts from the investigator the posi- 
tion of nonparticipation in one treatment method or an- 
other is favored, the ethics of "clinical equipoise" seem 
clear and should be considered by members of the SVS and 
the ISCVS-NA as they assess their participation i random- 
ized clinical trials designed to evaluate newer interventions 
as compared with the more standard operative procedures. 
During recent months, many of you have been asked 
to consider participation i CREST. In the summary state- 
ment about this clinical trial, an important credentialing 
phase for interventionalists who do not currently practice 
carotid angioplasty and stenting is described. Each clinical 
team, which would include an interventionalist, a neurolo- 
gist, and a vascular surgeon or nenrosurgeon, will partici- 
pate in the selection of 30 symptomatic patients who prefer 
management by angioplasty and stenting, while continu- 
ing to perform carotid endarterectomy for the significant 
majority of patients at their center. After these results are 
reviewed by an independent data safety and monitoring 
board, randomization of patients may proceed only if the 
targeted morbidity and mortality rates are at or below the 
defined upper limits of acceptability. Recognizing that as 
many as 50 to 60 centers will be involved in this effort, the 
credentialing phase simultaneously should reassure xperi- 
enced interventionalists that the newer centers can accom- 
plish the procedure with acceptably ow complication rates 
and should reassure the surgeons that safety and efficacy 
do, in fact, exist when rigorous clinical methods are applied 
to the assessment ofpatients. The executive committee of 
CREST has devoted the last 18 months to a series of 
clinical meetings ponsored by a private vascular founda- 
tion (Vascular Foundation of San Diego), as well as other 
industrial support. We are committed to submission of the 
grant to the National Institutes of Health no later than 
February 1, 1997, and recognize that funding will not be 
achieved before 1998. However, it is our opinion that this 
approach seems both ethical and clinically responsible, 
while also being consistent with the recent Joint Council 
"Point of View." 
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